We are driven by our mission to develop innovative solutions for neurodegenerative and neurodevelopmental diseases.
| Industry | Biopharmaceutical |
|---|---|
| Sector | New Drug Discovery |
| Fiscal Year-End | September 30 |
| Shares Issued and Outstanding | 82,112,511* |
| Stock Purchase Warrants | 160,000 ** |
| Stock Options | 14,109,363** |
| Fully Diluted | 96,355,874** |
| Cash | $143.8 million |
| Debt | Nil ** |
| Financial Statements & Filings | Anavex's filings can be found on EDGAR |
| Investor Relations | 1-844-689-3939
ir@anavex.com |
| Industry | Sector | Fiscal Year-End | Shares Issued and Outstanding |
|---|---|---|---|
| Biopharmaceutical | New Drug Discovery | September 30 | 82,112,511* |
| Stock Purchase Warrants | Stock Options | Fully Diluted | Cash |
|---|---|---|---|
| 160,000 ** | 14,109,363** | 96,355,874** | $143.8 million |
| Debt | Financial Statements & Filings | Investor Relations |
|---|---|---|
| Nil ** | Anavex's filings can be found on EDGAR | 1-844-689-3939
ir@anavex.com |
Presentations and Events
Stay up to date with Anavex’s participation in key conferences, presentations, and industry events. Explore how we’re sharing progress on our investigational therapies and advancing discussions about neurodegenerative and rare diseases.
Anavex’s leadership team and scientific advisors bring decades of experience in drug development, clinical research, and regulatory science. Their collective expertise guides our mission to advance innovative therapies for neurodegenerative and rare diseases. Together, they are driving Anavex’s commitment to delivering long-term value for stakeholders and making a meaningful difference in patients’ lives.
Anavex Life Sciences is followed by the analysts listed below. Please note that the opinions, estimates or forecasts regarding the performance of Anavex Life Sciences made by these analysts are theirs alone and do not represent the opinions, forecasts or predictions of Anavex Life Sciences or its management. Anavex Life Sciences, by reference or prior distribution, does not imply your endorsement or agreement with such information, conclusions or recommendations.
| Analyst | Firm |
|---|---|
| Raghuram Selvaraju PhD
Managing Director of Equity Research | H.C. Wainwright |
| Soumit Roy, PhD
Managing Director of Healthcare Research | Jones Trading |
| Jason Kolbert
Managing Director | EF Hutton |
We are dedicated to maintaining the highest standards of corporate governance. Our commitment to transparency, ethical conduct, and sound decision-making is at the core of how we operate. We believe that strong governance practices are essential to driving long-term value for our stakeholders while advancing our mission to develop innovative therapies for neurodegenerative and rare diseases.
Materials on this website may contain information about the future plans and prospects of Anavex Life Sciences Corp. and its representatives that constitute forward-looking statements for the purposes of the safe harbor provisions under the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as “expects,” “plans,” “intends,” “believes,” “will,” “estimates,” “forecasts,” “projects,” or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ materially from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in reports filed by Anavex Life Sciences Corp. with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Anavex Life Sciences Corp. undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Anavex Life Sciences Corp. cannot be sure when or if it will be permitted by regulatory agencies to undertake clinical trials or to commence any particular phase of any clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Anavex Life Sciences Corp. will obtain regulatory approval for any “phase” of clinical trials. We also cannot be sure of the clinical outcome with regards to efficacy or safety of our compounds. Potential investors should refer to the risk factors in our reports filed on Edgar.
In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, Anavex Life Sciences Corp. will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date.
